Rheumatoid Arthritis Completed Phase 3 Trials for Sirukumab (DB11803)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01856309Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003Treatment
NCT01606761A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)Treatment
NCT01604343A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)Treatment
NCT02019472A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid ArthritisTreatment
NCT01689532A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or SulfasalazineTreatment